Résumé
La réponse aux médicaments est souvent variable d’un individu à l’autre, ce qui rend parfois leur maniement délicat. La prédiction de la réponse devient un problème crucial en cas de fenêtre thérapeutique étroite de ces médicaments ou de l’existence d’alternatives thérapeutiques. Des facteurs génétiques affectant le métabolisme et le transport des médicaments expliquent en partie la variabilité interindividuelle dans la réponse. La pharmacogénétique étudie les mécanismes d’origine génétique intervenant dans la réponse aux médicaments dans le but d’optimiser les traitements médicamenteux, tant en termes d’efficacité que de sécurité d’emploi. L’existence de polymorphismes génétiques affectant les gènes codant pour les enzymes du métabolisme des médicaments aboutit à distinguer, dans la population générale, différentes classes d’individus en fonction de leur capacité métabolique vis-à-vis d’une enzyme donnée, à savoir des métaboliseurs lents, rapides et même parfois ultrarapides. Des méthodes de phénotypage et de génotypage permettent de déterminer ou de prédire le statut métabolique d’un individu et de savoir ainsi s’il présente un risque particulier d’inefficacité ou de toxicité vis-à-vis de certains médicaments. Plusieurs exemples d’applications cliniques (thiopurines, antivitamine K, codéine et tramadol) permettent d’illustrer l’intérêt de la pharmacogénétique pour la prise en charge des malades. La validation clinique d’un grand nombre d’analyses pharmacogénétiques et la mise au point de nouvelles technologies très performantes et peu coûteuses de génotypage vont contribuer au développement rapide de cette discipline dans la pratique médicale courante, avec la perspective d’une individualisation des traitements médicamenteux associée à l’amélioration du taux de réponse et la diminution des accidents iatrogènes.
Abstract
The narrow therapeutic index of most pharmaceutical agents and the severe consequences of undertreatment or overdosing have led to search for molecular predictive factors of toxicity and efficacy. Genetic factors involved in drug metabolism and transport partly explain inter-individual variability in drug response. Pharmacogenetics focuses on the molecular mechanisms involved in drug response. Its ultimate goal is to optimize the treatments, combining the better efficacy with the minimal risk of severe side-effects. Polymorphisms in genes encoding specific drugmetabolising enzymes may be encountered in some individuals and allow characterizing different groups in the general population as low, rapid and even ultra-rapid metabolisers. Phenotyping and genotyping tests are now available to determine or predict the metabolic status of an individual and, thus, enabling to evaluate the risk of drug failure or toxicity. Several clinical applications of pharmacogenetics (thiopurines, antivitamine K, codeine, and tramadol) have already been developed in the routine medical practice resulting in significant improvement in patient treatment. The clinical validation of an increasing number of pharmacogenetic tests as well as the development of new highly efficient technologies for genotyping should further promote pharmacogenetics in clinical practice and lead to the development of a patient-tailored drug therapy.
Références
Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200–1205
Pirmohamed M, James S, Meakin S, et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329:15–19
Pouyanne P, Haramburu F, Imbs JL, et al (2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 320:1036
Beaune PH, Loriot MA (2000) Molecular basis of individual susceptibility to xenobiotics: man and environment. MS. Médecine sciences 16:1051–1056
Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521–590
Xu C, Li CY, Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249–268
Renton KW (2000) Hepatic drug metabolism and immunostimulation. Toxicology 142:173–178
Allorge D, Loriot MA (2004) Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport. Ann Biol Clin (Paris) 62:499–511
Meyer UA (1991) Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics 1:66–67
Textoris J, Davidson J, Martin C, et al (2009) Role of genetics in anaesthesia-related variability. Ann Fr Anesth Reanim 28:564–574
Miheller P, Lakatos PL (2010) Thiopurines in Crohn’s disease, is there something new? Expert Opin Drug Metab Toxicol 6:1505–1514
Roblin X, Peyrin-Biroulet L, Phelip JM, et al (2008) A 6-thioguanine nucleotide threshold level of 400 pmol/8 × 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 1103:3115–3122
Lowry PW, Franklin CL, Weaver AL, et al (2001) Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49:665–670
Gisbert JP, Nino P, Rodrigo L, et al (2006) Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol 101:2769–2776
McLeod HL, Siva C (2002) The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3:89–98
Evans WE, Hon YY, Bomgaars L, et al (2001) Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19:2293–2301
Thervet E, Anglicheau D, Toledano N, et al (2001) Long-term results of TPMT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol 12:170–176
Dewit O, Starkel Problin X (2010) Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest 40:1037–1047
Oldenburg J, Watzka M, Rost S, et al (2007) VKORC1: molecular target of coumarins. J Thromb Haemost 5(Suppl 1):1–6
Ansell J, Hirsh J, Hylek E, et al (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:160S–98S
Rieder MJ, Reiner AP, Gage BF, et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293
Wadelius M, Chen LY, Downes K, et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262–270
Veenstra DL, You JH, Rieder MJ, et al (2005) Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 15:687–691
Sconce EA, Khan TI, Wynne HA, et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329–2333
D’Andrea G, D’Ambrosio RL, Di PernA P, et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645–649
Vecsler M, Loebstein R, Almog S, et al (2006) Combined genetic profiles of components and regulators of the vitamin Kdependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205–211
Carlquist JF, Horne BD, Muhlestein JB, et al (2006) Genotypes of the cytochrome P450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 22:191–197
Caldwell MD, Awad T, Johnson JA, et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106–4112
Perez-Andreu V, Roldan V, Lopez-Fernandez MF, et al (2010) Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost 8:1012–1017
Takeuchi F, McGinnis R, Bourgeois S, et al (2009) A genomewide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433
Zambon CF, Pengo V, Padrini R, et al (2010) VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 12:15–25
Yuan Hy, Chen JJ, Lee MT, et al (2005) A novel functional VKORC1 promoter polymorphism is associated with interindividual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745–1751
Aithal GP, Day CP, Kesteven PJ, et al (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719
Margaglione M, Colaizzo D, D’Andrea G, et al (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84:775–778
Higashi MK, Veenstra DL, Kondo LM, et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690–1698
Peyvandi F, Spreafico M, Siboni SM, et al (2004) CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 75:198–203
Sanderson S, Emery Jhiggins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97–104
Schwarz UI, Ritchie MD, Bradford Y, et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999–1008
Wadelius M, Chen LY, Lindh JD, et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784–792
Schalekamp T, Brasse BP, Roijers JF, et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80:13–22
Verstuyft C, Morin S, Robert A, et al (2001) Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 11:735–737
Epstein RS, Moyer TP, Aubert RE, et al (2010) Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 55:2804–2812
Vree Tb, Verwey-Van Wissen CP (1992) Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos 13:445–460
Mahgoub A, Idle JR, Dring LG, et al (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584–586
Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–833
Dayer P, Desmeules J, Leemann T, et al (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P450 dbl/bufI). Biochem Biophys Res Commun 152:411–416
Sindrup SH, Brosen K, Bjerring P, et al (1990) Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 48:686–693
Bertilsson L (2007) Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: clinical and interethnic aspects. Clin Pharmacol Ther 82:606–609
Poulsen L, Brosen K, Arendt-Nielsen L, et al (1996) Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51:289–295
Eckhardt K, Li S, Ammon S, et al (1998) Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76:27–33
Kirchheiner J, Schmidt H, Tzvetkov M, et al (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257–265
Gasche Y, Daali Y, Fathi M, et al (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827–2831
Ciszkowski C, Madadi P, Phillips MS, et al (2009) Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 361:827–828
Madadi P, Koren G, Cairns J, et al (2007) Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 53:33–35
Koren G, Cairns J, Chitayat D, et al (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeineprescribed mother. Lancet 368:704
Paar WD, Frankus Pdengler HJ (1992) The metabolism of tramadol by human liver microsomes. Clin Investig 70:708–710
Wu WN, Mckown Laliao S (2002) Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 32:411–425
Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43:879–923
Stamer UM, Stuber F, Muders T, et al (2008) Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 107:926–929
Ginsburg GS, Voora D (2010) The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 55:2813–2815
De Chaisemartin L, Loriot MA (2005) Pharmacogenetics of anticancer drugs. Pathol Biol (Paris) 53:116–124
Wang L, McLeod HL, Weinshilboum RM (2011) Genomics and drug response. N Engl J Med 364:1144–1153
Swen JJ, Nijenhuis M, DE Boer A, et al (2011) Pharmacogenetics: from bench to byte: an update of guidelines. Clin Pharmacol Ther 89:662–673
Author information
Authors and Affiliations
Corresponding author
Additional information
Cet article correspond à la conférence faite par l’auteur au congrès de la SRLF 2012 dans la session : Des traitements du futur.
Rights and permissions
About this article
Cite this article
Narjoz, C., Moreau, C., Beaune, P. et al. Intérêt clinique de la pharmacogénétique : anticiper les toxicités et mieux prédire l’efficacité des médicaments. Réanimation 21 (Suppl 2), 354–362 (2012). https://doi.org/10.1007/s13546-011-0336-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13546-011-0336-x